Evaluation of Direct Transfer to Angiography Suite vs. Computed Tomography Suite in Endovascular Treatment: Randomized Clinical Trial (ANGIOCAT) (ANGIOCAT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04001738 |
|
Recruitment Status :
Terminated
(Intermediate analysis)
First Posted : June 28, 2019
Last Update Posted : January 5, 2021
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Stroke, Acute | Other: Direct Transfer to Angio Suite | Not Applicable |
Prospective, randomized, open, treatment-blinded trial of acute stroke patients with suspected large vessel occlusion within 6 hours from symptoms onset in which two strategies will be compared: Direct Transfer to Angiography Suite (DTAS) vs. Computed Tomography Suite (DTCT). The study will be unicentric however there is the possibility of incorporating new stroke centers with previous experience of at least 50 DTAS cases.
The RACE scale (Rapid Arterial oCclusion Evaluation) will be used as a prehospital screening tool to identify acute stroke patients with suspicion of LVO. Once prenotifying the imminent arrival and the verified inclusion and exclusion criteria by the Neurologist at arrival, the patient will be randomized by an app in one of both study protocols.
Subjects will be followed up to 90 days post-randomization.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 174 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Evaluation of Direct Transfer to Angiography Suite vs. Computed Tomography Suite in Endovascular Treatment: Randomized Clinical Trial |
| Actual Study Start Date : | August 14, 2018 |
| Actual Primary Completion Date : | November 7, 2020 |
| Actual Study Completion Date : | November 7, 2020 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Direct Transfer to Angio Suite
After a fast neurological evaluation, patient will be direct transferred to angiography suite where endovascular treatment (EVT) team will be waiting for it. It will be done a cone beam-CT and if the image don't contraindicate endovascular treatment it will be performed and the large vessel occlusion will be confirmed by arteriography. If intravenous treatment have not been previously administered, it will be able to start in parallel.
|
Other: Direct Transfer to Angio Suite
Patient will be direct transferred to angiography suite where EVT team will be waiting for it. |
|
No Intervention: Direct Transfer to CT Scan
After a fast neurological evaluation, patient will be transferred to CT suite where usual image protocol will be performed (CT and CT-angio). Within 6 hours from onset CT perfusion could be required to take detections. Once interpreted image results, it will be decided intravenous and/or endovascular treatment.
|
- Clinical outcome measurde by modified Rankin Scale score (shift analysis) [ Time Frame: 90 days ]
Modified Rankin Scale score in ischemic stroke patients with large vessel occlusion as evaluated through a structured telephone-based interview performed by a central assessor who is blinded to group assignment.
Modified Rankin Scale measures functional status with a range from 0 (asymptomatic) to 6 (dead).
- Rate of patients with treatment associated complications. [ Time Frame: 72 hours ]Lack of treatment associated complications, mainly hemorrhagic transformation.
- Delay of inhospital times [ Time Frame: 8 hours ]Time from door to groin puncture
- Rate of dramatic improvement [ Time Frame: 24 hours ]10 NIHSS points drop or NIHSS <2
- Rate of good functional outcome [ Time Frame: 90 days ]Modified Rankin Scale score ≤2
- Rate of patients treated by endovascular treatment [ Time Frame: 8 hours ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Large vessel occlusion suspected acute stroke codes (RACE>4) within 6 hours from stroke onset which are prenotified from emergency medical system.
- Confirmed NIHSS>10 at arrival.
- Good pre-stroke functional status (mRS≤2)
- Angiography suite available.
- Endovascular treatment team available (Neurologist, Interventionist, anesthesiologist, Nursery, Technicians…)
Exclusion Criteria:
- Hemodynamically unstable patients who requires of advanced vital support.
- Patients with an advanced disease that conditions a life expectancy lower than 6 months.
- Participation in other clinical trial with a drug or device which could influence in the outcome.
- Patients with neurological or psychiatric disease that could confound future evaluations.
- Lack of disponibility for 90 days tracing.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04001738
| Spain | |
| Vall d'Hebron University Hospital | |
| Barcelona, Catalonia, Spain, 08035 | |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Manuel Requena Ruiz, Principal Investigator, Hospital Vall d'Hebron |
| ClinicalTrials.gov Identifier: | NCT04001738 |
| Other Study ID Numbers: |
PR(AG)156/2018 |
| First Posted: | June 28, 2019 Key Record Dates |
| Last Update Posted: | January 5, 2021 |
| Last Verified: | December 2020 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Endovascular treatment Large Vessel Occlusion |
|
Stroke Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Vascular Diseases Cardiovascular Diseases |